Nogapendekin Alfa Inbakicept-pmln (Anktiva) for NMIBC
Defines medical necessity and prior authorization criteria for Nogapendekin alfa inbakicept-pmln (Anktiva) when used with BCG to treat BCG-unresponsive non‑muscle invasive bladder cancer in adults; applies to Centene lines of business noted in the policy.
No material clinical or coverage changes in this revision.
Coverage Criteria for Nogapendekin alfa inbakicept-pmln (Anktiva)
Initial Therapy — Covered when ALL of the following are met for Initial Approval (Non‑Muscle Invasive Bladder Cancer)
Covered when ALL of the following are met for Initial Approval (Non‑Muscle Invasive Bladder Cancer):
Continuation Therapy — Covered when ALL of the following are met for Continuation/Renewal (patients already receiving therapy)
Covered when ALL of the following are met for Continuation/Renewal (patients already receiving therapy):
Non‑FDA approved indications that are not specifically addressed in this policy are not authorized for coverage unless the provider submits sufficient documentation of efficacy and safety in accordance with the applicable off‑label use policies (for example, CP.CPA.09 for commercial, HIM.PA.154 for Health Insurance Marketplace, or CP.PMN.53 for Medicaid) or unless the use is otherwise supported by the member's evidence of coverage.
Coverage determinations made under this policy are subject to all exclusions, limitations, and other terms contained in the member's benefit plan and evidence of coverage. This clinical policy provides guidance for medical necessity determinations and does not supersede or modify any specific contractual coverage language in a member's plan.
Requests for non‑FDA approved (off‑label) uses of Nogapendekin alfa inbakicept‑pmln that do not include adequate supporting evidence per the referenced off‑label use policies are not authorized for coverage.
Dosing and Regimens
| Regimen Component | Details |
|---|---|
| Induction | |
| 400 mcg administered intravesically with BCG once weekly for 6 weeks (second induction may be given if complete response not achieved at month 3). | |
| Maintenance | |
| 400 mcg administered intravesically with BCG once weekly for 3 weeks at months 4, 7, 10, 13 and 19 (with possible addition of months 25, 31, and 37); maximum treatment duration 37 months. |
Billing and Codes
| J9028 | Injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 microgram |
Provider Requirements and Actions
Prior Authorization Required
Prior authorization required. Approval is contingent on meeting the indication, age, prescriber, documented BCG‑refractory status, dosing limits, and other clinical criteria outlined in the policy. Provider must submit sufficient clinical documentation (e.g., office notes, pathology reports, lab results, prior treatment records) to demonstrate all approval criteria are met.
- Prior authorization may be required for BCG immunotherapy per policy Appendix D.
- Dose limits: ≤400 mcg (1 vial) per week unless supported by practice guidelines or peer‑reviewed literature with prescriber justification.
- Requests for continuation or dose increases must document current therapy, response to therapy, and total treatment duration limits.
Required Clinical Documentation
Provider must submit documentation (such as office/chart notes, labs, pathology, and prior treatment records) supporting that the member meets all approval criteria. Insufficient documentation or failure to demonstrate required clinical criteria may result in denial.
- Examples of required documentation: pathology confirming CIS or Ta/T1 high‑grade with concomitant CIS, records showing BCG‑refractory status, documentation of prescriber consultation with an oncologist, and dosing rationale if exceeding standard limits.
Therapeutic Alternative (BCG)
Therapeutic alternative: Intravesical Bacillus Calmette‑Guérin (TICE BCG) is the preferred alternative and may be considered or required prior to Anktiva per the approval criteria and Appendix B. BCG products may themselves require prior authorization per applicable formularies and benefit rules.
- Appendix B lists TICE BCG dosing (1 to 8 x 10^8 CFU per vial; once weekly for induction).
- Providers should consider BCG therapy where clinically appropriate before initiating Anktiva, consistent with the policy's stepwise criteria.
Coverage Document Adherence
Coverage decisions and administration of benefits are subject to the member's evidence of coverage, certificate of coverage, policy, contract, and all applicable terms, conditions, exclusions, and limitations. This clinical policy is a guide to medical necessity and does not guarantee payment. Providers are responsible for understanding and complying with Health Plan contractual terms; providing services or submitting claims implies agreement to those terms.
- State and federal requirements and Health Plan‑level administrative policies also apply.
- For Medicaid members, state Medicaid coverage provisions take precedence when conflicting with this policy.
Definitions and Abbreviations
Background
Nogapendekin alfa inbakicept‑pmln (Anktiva) is an interleukin‑15 receptor agonist indicated in combination with Bacillus Calmette‑Guérin (BCG) for the treatment of adult patients with BCG‑unresponsive non‑muscle invasive bladder cancer (NMIBC), including carcinoma in situ (CIS) with or without papillary tumors. The approved intravesical regimen includes an induction course and a maintenance schedule; dosing guidance and treatment duration are specified in the prescribing information and supporting guidance used to determine medical necessity.
This clinical policy was developed by qualified health care professionals after review of available standards of care, peer‑reviewed literature, and regulatory guidance, and is intended to guide coverage and prior authorization decisions for Anktiva used with BCG.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.